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A turn in the road: How studies on the
pharmacology of glucosylceramide synthase
inhibitors led to the identification of a lysosomal
phospholipase A2 with ceramide transacylase
activity
James A. Shayman, Akira Abe and Miki Hiraoka
Division of Nephrology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
A series of inhibitors of glucosylceramide synthesis, the PDMP based family of compounds, has been developed as a tool
for the study of sphingolipid biochemistry and biology. During the course of developing more active glucosylceramide syn-
thase inhibitors, we identified a second site of inhibitory activity for PDMP and its structural homologues that accounted for
the ability of the inhibitors to raise cell and tissue ceramide levels. This inhibitory activity was directed against a previously
unknown pathway for ceramide metabolism, viz. the formation of 1-O-acylceramide. In this pathway the addition of a fatty
acyl group to the primary hydroxyl of ceramide occurs through a transacylation with either phosphatidylethanolamine or
phosphatidylcholine as a substrate. However, both in the absence and presence of ceramide, water serves as an acceptor
for the fatty acid. Thus the enzyme may be considered to be a phospholipase A2. The enzyme is unique in that it has an
acidic pH optimum and is localized to lysosomes by cell fractionation. More recently, the 1-O-acylceramide synthase has
been purified, sequenced, and cloned. This phospholipase A2 was discovered to be structurally homologous to lecithin
cholesterol acyltransferase (LCAT). However, this phospholipase A2 does not recognize cholesterol and lacks the defined
lipoprotein-binding domain present in LCAT. We now refer to this enzyme as lysosomal phospholipase A2 (LPLA2). Al-
though acidic phospholipase A2 activities have been previously identified, LPLA2 appears to be the first lysosomal PLA2
to have been sequenced. This new phospholipase A2 lacks an obvious and proven biological function.
Published in 2004.
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Introduction
Great strides have been made in our understanding of the bio-
chemistry and biology of glycosphingolipids over the past 40
years. This is in no small part due to the contributions of Pro-
fessors Robert Ledeen and Yoshitaka Nagai. It is therefore with
great admiration that we are providing this review in their honor.
Typical of their work and of many other investigators during
this time is the observation that the study of glycosphingolipids
has resulted in many unexpected insights into a diverse range
of biochemical and cellular processes for sphingolipids. These
phenomena include cell signaling [1], growth and differentia-
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tion [2,3], stress responses [4], and oncogenesis [5] to name
a few. Our own work has primarily focused on the pharmacol-
ogy of small molecule inhibitors of glucosylceramide synthase.
These compounds, typified by 1-phenyl-2-decanolamino-3-
morpholinopropanol (PDMP), have been used to probe the
functions of glycosphingolipids [6]. In the course of developing
these compounds and studying their specificity, we discovered
that the PDMP homologues inhibited the metabolism of ce-
ramide through a novel pathway. This pathway is the formation
of 1-O-acylceramide.1 This review traces the discovery of this
pathway, its characterization, and the identification of the en-
zyme that catalyzes the formation of this unique sphingolipid.
Ceramide metabolism and signaling pathways
Considerable experimental work was published establishing a
key role for glycerolipids in cell signaling events long before
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comparable functions were considered for sphingolipids. How-
ever, over the past fifteen years, a large corpus of work has
demonstrated several potentially important roles for sphin-
golipids. These sphingolipids include the long chain bases such
as sphingosine [7], sphingosine-1-phosphate [8], ceramide [9],
ceramide-1-phosphate [10], and multiple glycosphingolipids.
Among these sphingolipids, two have received particular at-
tention as cell signaling molecules. These include sphingosine-
1-phosphate and ceramide. The former lipid has been demon-
strated to be the ligand for several members of the Edg receptor
family [11]. Sphingosine-1-phosphate is also generated within
cells. In both cases the primary effect is to promote cellular
proliferation. The latter compound, ceramide, has been sug-
gested to exert the opposite effect on cells, viz. growth arrest
and apoptosis. A considerable number of publications support
this hypothesis. Clearly, an understanding of the pathways for
ceramide metabolism and the regulation of these pathways is
important in proving the role that ceramide plays in these crit-
ical cellular events.
Ceramide is formed as part of the pathway for long
chain base synthesis and acylation. It is also the key in-
termediate in the formation of most of the biologically
important sphingolipids. Products of ceramide metabolism
include sphingomeylin, cerebrosides (glucosylceramide and
galactosylceramide), ceramide-1-phosphate, and ceramide-
phosphoethanolamine. Less prominent pathways for ce-
ramide metabolism also exist. Indeed, the formation of 1-O-
acylceramide and more specifically the enzyme that catalyzes
its synthesis is the subject of this review.
The formation of ceramide during cell signaling events is
proposed to occur in one of two ways. First, ceramide may be
generated through the activation of an acidic or neutral sph-
ingomyelinase. Numerous agonists have been demonstrated to
cause cellular ceramide accumulation through activation of sph-
ingomyelin hydrolysis. Second, ceramide may be formed by de
novo synthesis. A smaller number of agonists have been shown
to stimulate cellular ceramide accumulation through the de novo
pathway. Most examples of de novo ceramide synthesis are as-
sociated with cellular responses to stress or toxins leading to
programed cell death. Recently it has been suggested that a ther-
apeutic strategy for promoting cell death via ceramide would
be to simultaneously block multiple pathways for ceramide
metabolism [12]. Fully characterizing the alternative pathways
for ceramide metabolism, understanding their relative contri-
butions and subcellular localization would be prerequisites for
exploiting this approach.
The phospholipase A2 family of enzymes
The phospholipase A2 superfamily is comprised of a broad
range of enzymes that share the ability to hydrolyze the sn-2
ester bond of phospholipids [13]. The products of this reaction,
free fatty acid and lysophospholipid, have important biological
roles. The former is not only an important source of cellular en-
ergy, but is also the substrate for additional cellular messengers
in the form of arachidonate metabolites. The latter products play
signaling roles in addition to having important effects on mem-
brane remodeling and membrane perturbation. Historically the
phospholipase A2s were thought to be small, secreted enzymes
characterized by having a catalytic histidine, calcium depen-
dence and disulfide rich polypeptides. The family of enzymes
greatly expanded with the discovery of cytosolic PLA2 activ-
ity without disulfide bonds and characterized by presence of a
catalytic serine.
Currently there are eleven groups of phospholipase A2s. For
a candidate phospholipase A2 to be categorized as a member of
a novel group, four criteria should be met [14]. These include
the ability to catalyze the hydrolysis of the sn-2 ester bond of
a phospholipid, the identification of its complete amino acid
sequence, the identification of all enzymes with identifiable
sequence homology (paralogs being assigned subgroup letters),
and the identification of splice variants.
Groups I, II, III, V, IX, X, and XI utilize a catalytic histidine
and are of small molecular weight (13–15 kDa) [15]. Groups IV,
VI, VII, and VIII utilize a neuclophilic serine and have little or
no Ca2+ requirement for catalysis. The molecular weights are
larger (26–114 kDa). Many members of these latter groups have
C2 domains, are members of the α/β fold hydrolase proteins,
and may contain a required Ser/His/Asp triad for activity [16].
Lysosomal phospholipase A2 activities have been previously
documented both within mammalian tissues and pathogens. The
demonstration of the existence of a unique lysosomal phospho-
lipase A2 by the criteria outlined above has been more problem-
atic. In 1997 the sequence of a protein was reported with Ca2+
independent phospholipase A2 activity at pH 4.0 [17]. The ac-
tivity of the putative lysosomal phospholipase A2 was reported
blocked by two serine hydrolase inhibitors. However, mutagen-
esis of the serine and cysteine had no effect on its phospholipase
A2 activity [18]. It was later demonstrated that this enzyme was
a non-selenium glutathione peroxidase and not a phospholipase
A2 [19]. Thus until recently the structure and nature of the en-
zyme associated with the lysosomal phospholipase A2 activity
was not defined.
Discovery and characterization of the 1-O-acylceramide
synthase pathway
Most mammalian glycosphingolipids are formed from the se-
quential addition of sugars to glucosylceramide. This cerebro-
side is formed from ceramide and UDP-glucose and is catalyzed
by glucosylceramide synthase. Because glucosylceramide ac-
cumulates in Gaucher disease, it was hypothesized that inhi-
bition of glucosylceramide synthase could be used as a strat-
egy for the treatment of this and other glycosphingolipidoses
[20]. An effort was undertaken to develop small molecule
inhibitors of glucosylceramide synthase. D-threo-1-Phenyl-2-
decanoylamino-3-morpholino-propanol (PDMP) was identi-
fied as a specific inhibitor of the synthase with an IC50 of 20 µM
[21]. The other enantiomers, D-erythro, L-threo- and L-erythro,
had no inhibitory activity against the synthase (Figure 1).
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Figure 1. Structural enantiomers of PDMP.
D-threo-PDMP was found to have dose limiting toxicity, how-
ever, and this was initially believed to be secondary to the ac-
cumulation of ceramide resulting from substrate accumulation.
This interpretation was subsequently found to be incorrect when
more active homologues of PDMP were developed.
Substitutions of a palmitoyl group for the decanoyl group
and of a pyrrolidino group for the morpholino group re-
sulted in a homologue of increased activity (IC50 ca. 1 µM)
[22]. Careful study of this new homologue, D-threo-1-phenyl-
2-palmitoylamino-3-pyrrolidino-propanol (P4), revealed that
while glucosylceramide depletion occurred at a low concen-
tration of inhibitor, ceramide accumulation was only present
at 20-fold higher concentrations. Surprisingly, when a homo-
logue was synthesized that replaced an aliphatic group for the
phenyl group, inhibition of glucosylceramide synthesis was ob-
served without ceramide accumulation. Furthermore, when the
inactive enantiomers of P4 were tested, these compounds were
inactive as glucosylceramide synthase inhibitors but compara-
bly active in causing the accumulation of ceramide (Table 1).
These results suggested that PDMP and P4 caused the accu-
mulation of ceramide by inhibition of a second ceramide utiliz-
ing enzyme. A search was undertaken to identify this enzyme.
Several known ceramide-utilizing enzymes were assayed in-
cluding sphingomyelin synthase, acid and alkaline ceramidase,
acid and neutral sphingomyelinase, and ceramide synthase. No
inhibitory activity by P4 against any of these enzymes could be
detected.
A different strategy was then employed. A short chain ce-
ramide was synthesized that was radiolabeled in the long chain
base [23]. This C2 ceramide was avidly metabolized to free
sphingosine, long chain ceramides, and short and long chain
sphingomyelin and glucosylceramide. However, another highly
Table 1. Effects of selected PDMP homologues on glucosylceramide synthase activity, ceramide and cell proliferation in MDCK cells
Glucosylceramide [ 3H]Thymidine
synthase activity Ceramide incorporation Cell protein
Compound (percent inhibition) (percent control) (percent control) (percent control)
D,L-threo-P4 (4 µM) 86.5 ± 0.4 368 45.7 ± 5.5 34.8 ± 6.1
D,L-erythro-P4 (4 µM) 15.4 ± 1.4 438 51.5 ± 0.9 31.2 ± 5.7
1-Pyrrolidino-1-deoxyceramide (2 µM) 79.1 ± 0.2 100 100 101 ± 2.4
Figure 2. Products of N-acetylsphingosine metabolism in
MDCK cells. MDCK cells (1.35 × 106) were seeded into 15-cm
dishes in defined medium for 24 h. The medium was replaced
with fresh medium containing 10 µM N-acetyl-[3H]sphingosine
(6.9 × 105 cpm/dish), and the cells were incubated for 1, 4, or
10 h. The total lipids were extracted and analyzed as previously
reported. Reprinted with permission of The American Society
of Biochemistry and Molecular Biology [23].
lipophilic compound was formed (Figure 2). This novel ce-
ramide metabolite was structurally characterized as follows.
The product was subjected to alkaline methanolysis yielding the
substrate (N -acetylsphingosine). This finding suggested that
the product represented an acylated ceramide with base sensi-
tive acyl linkages. Two potential acylation sites were available,
the 1 and 3 hydroxyl positions. Hydroxyls vicinal to a double
bond are oxidized by 2,3-dichloro-5,6-dicyanobenzoquinone.
Thus the 1 but not 3 hydroxyl of 1-O-acyl-N -acetylsphingosine
should be susceptible to acylation following treatment with this
compound. This was indeed found to be the case. When 1-O-
acyl-N -acetylsphingosine was incubated with the quinone, the
corresponding ketone was formed consistent with acylation at
the 1-hydroxyl position. The novel sphingolipid was thus iden-
tified as 1-O-acylceramide.
The source of the fatty acid remained to be determined.
Free fatty acid and fatty acylCoA were considered as potential
substrates. Free fatty acids of varying chain length and satu-
ration as well as fatty-acyl CoAs were inactive or inhibitory.
However, upon the addition of liposomes incorporating phos-
phatidylcholine or phosphatidylethanolamine, a marked en-
hancement of activity was observed (Table 2). These data were
consistent with the formation of 1-O-acylceramide through the
transacylation with the phospholipid as substrate (Figure 3).
The specificity of the reaction for sn-1 versus sn-2 fatty acids
was next evaluated. When authentic phosphatidylethanolamine
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Table 2. Comparison of different acyl donors for transacylation of N-acetylsphingosine
Transacylation activity (pmol/min/mg protein)
Phospholipid concentration (µM) DOPC DOPC:PE DOPC:sulfatide DOPC:PE:sulfatide
1.28 15, 11
12.8 40, 62 41, 43 93, 110 265, 261
128 18, 16 97, 59 288, 298 474, 486
640 0, 0 272, 268 95, 109 150, 144
The reaction mixture consisted of 47 mM sodium citrate (pH 4.5), 10 µM N-acetyl-[3H]sphingosine, 30–60 ug/ml of MDCK cell supernatant, and
128 mM liposomal phospholipid. The molar ratios of the mixed liposomes were 70:30 for DOPC:PE, 86:14 for DOPC:sulfatide, and 61:25:14 for
DOPC:PE:sulfatide. The incubation was for 20 min at 37◦C. DOPC and PE denote dioctanoylphosphatidylcholine and phosphatidylethanolamine
respectively.
Figure 3. Proposed pathway for the synthesis of 1-O-
acylceramide.
containing tritiated arachidonate in the sn-2 position was used
as substrate, radiolabeled 1-O-acylceramide was formed. In
addition, free arachidonate was released. This experiment pro-
vided the first suggestion that in the absence of ceramide as
an acceptor, 1-O-acylceramide synthase could function as a
phospholipase A2.
In order to more definitively demonstrate that the activity in
question was that of a phospholipase A2, the 1-O-acylceramide
synthase was purified [24]. A survey of rat tissues revealed that
the activity was ubiquitously present; however, the specific ac-
tivity was highest in the brain. The protein was, therefore, puri-
fied from bovine brain with a 193,000-fold increase in specific
activity yielding a single band by Coomassie blue staining. Of
note was a very significant enrichment of the protein by elu-
tion over a concanavalin A column with α-methyl mannoside
elution, consistent with the enzyme being mannose rich.
The characterization of the purified enzyme revealed the fol-
lowing properties. The molecular mass was ca. 40 kDa and it
was a glycoprotein of a single polypeptide chain. The purified
enzyme had a pH optimum of 4.5. The divalent cations Ca2+ and
Mg2+ enhanced but were not required for transacylase activity.
The enzyme was neither activated nor inhibited in the presence
of ATP or thiol reagents such as dithiothreitol and NEM. Thus
the enzyme differs from groups I, II, and III phospholipase A2s
which are highly sensitive to such reagents. The phospholipase
A2 inhibitors bromoenollactone (BEL) and nonadecyltetraenyl
trifluoromethyl ketone (AACOF3) did not inhibit the enzyme
activity. Thus inhibitors of both the calcium dependent and cal-
cium independent cytosolic phospholipase A2s of the higher
molecular weights were inactive against the 1-O-acylceramide
synthase. Importantly, in the absence of N -acetylsphingosine,
the enzyme acted as a phospholipase A2 using water and not
N -acetylsphingosine as an acceptor (Figure 4).
Figure 4. Dual enzyme activity of 1-O-acylceramide synthase.
The transacylase and phospholipase A2 activities of 1-O-
acylceramide synthase purified from bovine brain were mea-
sured. The reaction was conducted using liposomes containing
L-α-1-acyl-2-[1-14C]arachidonoyl-phosphatidylethanolamine in
the presence or absence of 10 µM N-acetylsphingosine as
previously reported [24]. Free aracidonic acid was released
in the absence of N-acetylsphingosine. Both free arachidonic
acid and 1-O-acylceramide were formed in the presence of N-
acetylsphingosine. Reprinted with permission of The American
Society of Biochemistry and Molecular Biology [24].
Cloning and further characterization
of 1-O-acylceramide synthase
The purified protein was subjected to tryptic digestion and
the fragments were sequenced by mass spectrometry [25]. A
BLAST search revealed that the partial amino acid sequences
were highly homologous to the amino acid sequence deduced
from the human cDNA encoding a protein termed LCAT-like
lysophospholipase (LLPL) [26]. Several ESTs were identified
following a T BLAST N data search of the GenBank/EBI Data
Bank, including bovine ESTs. Primers were subsequently de-
signed and the entire coding sequences for the bovine and mouse
coding sequences were obtained. The entire coding sequences
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of the mouse, bovine, and human genes were obtained from
the respective kidney total RNA by RT-PCR using primer se-
quences designed on the basis of the EST sequences. The as-
signed GenBank accession numbers of the mouse and bovine
sequences are AF468958 and AY072914 respectively.
A comparison of the deduced amino acid sequences from
the human, mouse, and bovine genes was made. The human
and mouse cDNAs encode 412 amino acid polypeptides with
an acidic isoelectric point. The bovine cDNA encodes a 407
amino acid polypeptide with a basic isoelectric point. A pre-
dicted signal peptide sequence exists for all three polypeptides.
In addition, there are several putative N-linked glycosylation
sites (three in the bovine protein, four in the mouse and hu-
man proteins). There is also a putative lipase motif, AXSXG,
predicted for each protein. This motif is also found in Bacillus.
In order to prove that the derived sequence encoded for 1-O-
acylceramide synthase activity, the entire open reading frame
of the mouse gene was cloned into the HindIII and XhoI sites of
pcDNA3 to generate carboxyl-terminally tagged proteins with
or without FLAG, HA, or c-Myc peptides. The vectors were
transfected into COS-7 cells. Both 1-O-acylceramide synthase
and phospholipase A2 activities were observed in each trans-
fected cell preparation. The presence of the carboxyl terminal
tag had no effect on activity. Immunoprecipitates of the tagged
proteins revealed that the phospholipase and transacylase ac-
tivities were intrinsic to the expressed proteins and that these
did not represent a cofactor or activator of another enzyme
(Figure 5).
Figure 5. Demonstration that LLPL has both transacylase and
phospholipase activities. Cells were transfected with carboxyl-
terminally c-Myc-tagged mouse LLPL. LLPL was recovered with
an anti-c-Myc monoclonal antibody in the presence or absence
of c-Myc or hemaglutinin peptide. The transacylase activity
was measured in soluble cell fraction as previously described.
Reprinted with permission of The American Society of Biochem-
istry and Molecular Biology [25].
Taniyama et al. [26] reported that human recombinant
LLPL has lysophospholipase activity. Cells transfected with
the mouse synthase demonstrated no lysophospholipase ac-
tivity under the conditions employed by these investigators
at either acidic or neutral pH. Because the deduced amino
acid sequence of the coding region of the gene is 49% ho-
mologous with lecithin cholesterol acyl transferase (LCAT),
we studied whether the expressed synthase has any LCAT ac-
tivity. Although marked phospholipase A2 activity was ob-
served in the presence of cholesterol and phosphatidylcholine,
no LCAT activity was observed. Thus although both 1-O-
acylceramide synthase (LLPL) and LCAT have phospholipase
A2 and transacylase activities, they recognize different accep-
tors. A review of the predicted secondary structures of the
two proteins reveals that they are structurally homologues near
their catalytic domains, but vary markedly at the cholesterol
and lipoprotein binding domains of LCAT. A recently pub-
lished dendrogram also reveals a distant relationship to phos-
pholipid:diacylglycerol acyltransferase.
Based on the submission of the cDNA sequence to the NCBI
by Taniyama et al. the human gene has been assigned the abbre-
viation LYPLA3 for lysophospholipase 3 [26]. Given that the
expressed protein has no detectable lysophospholipase activity,
this terminology should probably be changed. Gene mapping
reveals a location at 16q22.2. LCAT maps to 16q22.1, and there
are currently six genes mapped between LCAT and LYPLA3.
The mapping data suggests that LYPLA3 may have arisen as a
gene duplication in the remote past.
The localization of 1-O-acylceramide synthase has also been
evaluated. The enzyme activity was assayed in MDCK cell ho-
mogenates that were subjected to Percoll gradient fractionation.
Under these conditions the enzyme activity co-localized with
that of β-hexosaminidase. This is consistent with a lysosomal
localization of the enzyme.
In order to demonstrate that the AXSXG motif was the site
of the catalytically active serine, a serine-to-alanine substitu-
tion was made using the overlap extension method. The solu-
ble fraction from cells transfected with the mutated construct
failed to show any phospholipase A2 or transacylase activities.
Western blots revealed, however, that the mutated protein was
expressed at levels to that of the 1-O-acylceramide synthase
(Figure 6). This observation is consistent with the view that the
serine residue in the AXSXG motif is an active site and that the
enzyme forms an acyl-enzyme intermediate via the hydroxyl
group of serine. In addition, the catalytic triad of serine 181,
aspartic acid 345, and histidine 377 observed in LCAT is also
found in the 1-O-acylceramide synthase. This triad is more
generally characteristic of the α, β hydrolase fold proteins.
Thus 1-O-acylceramide synthase (LLPL) appears to fulfill
several criteria for being defined as a unique phospholipase A2.
It is capable of hydrolyzing fatty acids from the sn-2 position of
both phosphatidylcholine and phosphatidylethanolamine. The
complete amino acid sequence has been defined. Like several
other phospholipase A2s, 1-O-acylceramide synthase contains
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Table 3. Comparison of 1-O-acylceramide synthase (LPLA2) to cloned high molecular weight PLA2s
Common Size sn-2 fatty acid Calcium Expression
Group name Species (kDa) Chromosome preference requirement Activity profile profile
IVA cPLA2-α All 85 hu 1 AA Yes AACOF3 sensitive Ubiquitous
IVB cPLA2-β Human 100 hu 15 None Yes ND Ubiquitous
IVC cPLA2-γ Human 55 hu 19 AA No ND Ubiquitous
VIA iPLA2-β All 60 hu 22 None No BEL, ATP sensitive Ubiquitous
VIB IPLA2-γ Human 80–88 hu 7 None No BEL, ATP sensitive Heart, brain,
placenta
LPLA2, ACS, Mouse, cow, 40 hu 16 Yes No AACOF3, BEL, and Ubiquitous
LLPL human ATP insensitive
LYPLA3
This table excludes group VII and VIII phospholipase A2s that are also PAF acetyl hydrolases.
Figure 6. Expression of mouse LLPL and mutated LLPL in
COS-7 cells. COS-7 cells were transiently transfected with
pcDNA3, pcDNA3-c-Myc-tagged mouse LLPL, or pcDNA3-
cMyc-tagged mutated mouse LLPL. The soluble fractions, ob-
tained from the transfected cells, were assayed for transacy-
lase activity (A) or Western blotting (B) as previously described.
Reprinted with permission of The American Society of Biochem-
istry and Molecular Biology [25].
a catalytically active serine. Mutagenesis of this site abolishes
the phospholipase A2 activity. It is phylogenetically related to
a larger family of lipases, including LCAT. However, unlike
other groups of phospholipase A2s, the new phospholipase A2
has an acidic pH optimum, is mannose rich, and is localized to
lysosomes. The phospholipase has a unique activity profile and
chromosomal location. A comparison to other high molecular
weight phospholipase A2s is provided in Table 3.
Conclusions and future questions
The work reviewed in this paper can be summarized as follows.
First, enantiomers of the glucosylceramide synthase inhibitors
PDMP and P4 are equally active at raising cell ceramide levels
by inhibition of a pathway that does not involve glucosylce-
ramide synthesis. Second, this pathway is novel and consists
of the formation of 1-O-acylceramide through the transacyla-
tion of ceramide at the 1-hydoxyl position. The fatty acid is
donated from the sn-2 position of phosphatidylethanolamine or
phosphatidylcholine. Third, by purification the transacylase is
mannose rich and active at an acidic pH optimum. In the ab-
sence of ceramide, water may be used as an acceptor. Therefore
the enzyme acts as a phospholipase A2. Fourth, sequence anal-
ysis reveals that the enzyme is 49 percent identical to LCAT
and is a member of the α,β-hyrolase fold family of enzymes.
The human gene is identical to a previously described gene
names LLPL for LCAT-like lysophospholipase. However, the
expressed protein lacks significant lysophospolipase activity.
Fifth, the enzyme can be localized to lysosomes by cell frac-
tionation. Sixth, it contains a critical serine at the catalytic site.
It is calcium independent and is not inhibited by AACOF3 or
BEL. 1-O-Acylceramide synthase is, therefore, a novel lysoso-
mal phospholipase A2.
Several questions emerge from these observations and re-
main the subject of ongoing studies. We believe that two ques-
tions are particularly significant. First, is the formation of 1-
O-acylceramide a biologically important pathway or is water
the preferred acceptor for the lysosomal phospholipase A2?
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While it has been possible to measure endogenous levels of
1-O-acylceramide, the levels of this sphingolipid are very low
compared to those of ceramide or free sphingosine. In addition,
other alcohols serve as acceptors for the synthase and thus other
acylated alcohols may occur naturally. Finally, the hydrolysis
of phosphatidylcholine or phosphatidylethanolamine with the
formation of free fatty acid may be the biologically relevant
pathway. We anticipate that the development of in vitro and
in vivo models with the elimination or overexpression of the
lysosomal phospholipase A2 activity will clarify this issue.
Second, what is the biological role of the lysosomal phos-
pholipase A2? Little work has been done on defining the func-
tional significance of lysosomal phospholipase A2 activity. Two
approaches, however, are intriguing and potentially important.
The first and more obvious approach has been the consideration
of a role for lysosomal phospholipase A2 on the metabolism of
endogenous phospholipids. Fisher et al. have studied one ex-
ample of this type of activity. They have argued that an alveo-
lar macrophage lysosomal phospholipase A2 is critical for sur-
factant turnover [27]. A model for the study of this activity
is the rat lung in which dipalmitoylphosphatidylcholine is the
major phospholipid component. The metabolism of this lipid
is dependent on a lysosomal enzyme with phospholipase A2
activity and an acidic pH optimum. A second and less obvi-
ous consideration would be a role for lysosomal phospholipase
A2 in the metabolism of exogenously incorporated phospho-
lipids that might occur via the phagocytosis of microbes. When
macrophages are exposed to mycobacteria, a lysosomal phos-
pholipase A2 activity is required for the metabolism of cardi-
olipid within the cell wall [28]. This has been proposed to be
important for host defense and the prevention of proliferation
of the mycobacteria within the phagosome. While these are in-
triguing clues to the potential biological role of the lysosomal
phospholipase A2, the ubiquitous expression of the enzyme sug-
gests that there are functions for this phospholipase that extend
beyond the macrophage.
Note
1. For historical accuracy, the enzyme described in this paper, 1-O-
acylceramide synthase, has been given several names with associated abbre-
viations. For cogency, these are listed as follows: ACS, 1-O-acylceramide
synthase; LLPL, LCAT-like lysophospholipase; LYPLA3, lysophospholi-
pase 3; LPLA2, lysosomal phospolipase A2.
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